Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Volution Immuno Pharmaceuticals SA

Division of Akari Therapeutics PLC

Latest From Volution Immuno Pharmaceuticals SA

Akari Hopes Tick-Based Drug Will Be Safer, Cheaper Than Alexion's Soliris

Akari Therapeutics is looking to ticks to provide a new therapy that it hopes will offer a safer and cheaper alternative to Alexion Pharmaceuticals' Soliris for some rare orphan diseases.

Clinical Trials Companies

Deals Shaping The Medical Industry, September 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2015.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Akari Therapeutics PLC
  • Senior Management
  • Ray Prudo, MD, CEO
    Clive Richardson, COO
    Miles Nunn, CSO
  • Contact Info
  • Volution Immuno Pharmaceuticals SA
    6 Place des Eaux-Vives
    P.O. Box 3461 Geneva, 1211